Immutep (ASX:IMM) ended the fiscal third quarter with a cash balance of AU$92.5 million, according to a Tuesday filing with the Australian bourse.
It also has short-term bank deposits of AU$53.8 million, the filing said.
The clinical-stage biotechnology company saw progress in its ongoing trials during the quarter. This year, it expects analysis and safety assessment reports for treatments of breast cancer and autoimmune disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。